These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 1711873)

  • 41. A closed perfusion system with heparin coating and centrifugal pump improves cardiopulmonary bypass biocompatibility in elderly patients.
    Lindholm L; Westerberg M; Bengtsson A; Ekroth R; Jensen E; Jeppsson A
    Ann Thorac Surg; 2004 Dec; 78(6):2131-8; discussion 2138. PubMed ID: 15561050
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Methylprednisolone prophylaxis protects against endotoxin-induced death in rabbits.
    Jansen NJ; van Oeveren W; Hoiting BH; Wildevuur CR
    Inflammation; 1991 Apr; 15(2):91-101. PubMed ID: 1649135
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Doxycycline reduces cardiac matrix metalloproteinase-2 activity but does not ameliorate myocardial dysfunction during reperfusion in coronary artery bypass patients undergoing cardiopulmonary bypass.
    Schulze CJ; Castro MM; Kandasamy AD; Cena J; Bryden C; Wang SH; Koshal A; Tsuyuki RT; Finegan BA; Schulz R
    Crit Care Med; 2013 Nov; 41(11):2512-20. PubMed ID: 23928836
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of dexamethasone on perioperative renal function impairment during cardiac surgery with cardiopulmonary bypass.
    Loef BG; Henning RH; Epema AH; Rietman GW; van Oeveren W; Navis GJ; Ebels T
    Br J Anaesth; 2004 Dec; 93(6):793-8. PubMed ID: 15377582
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Granulocyte superoxide anion and elastase release during cardiopulmonary bypass.
    Haga Y; Hatori N; Yoshizu H; Okuda E; Uriuda Y; Tanaka S
    Artif Organs; 1993 Oct; 17(10):837-42. PubMed ID: 8274101
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Plasminogen activator inhibitor activity is associated with raised lactate levels after cardiac surgery with cardiopulmonary bypass.
    Dixon B; Santamaria JD; Campbell DJ
    Crit Care Med; 2003 Apr; 31(4):1053-9. PubMed ID: 12682472
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Coronary trapping of a complement activation product (C3a des-Arg) during myocardial reperfusion in open-heart surgery.
    Semb AG; Vaage J; Sørlie D; Lie M; Mjøs OD
    Scand J Thorac Cardiovasc Surg; 1990; 24(3):223-7. PubMed ID: 2293362
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The effect of continuous low dose methylprednisolone infusion on inflammatory parameters in patients undergoing coronary artery bypass graft surgery: a randomized-controlled clinical trial.
    Ghiasi A; Shafiee A; Salehi Omran A; Ghaffari-Marandi N; Shirzad M; Barkhordari K
    Acta Med Iran; 2015; 53(2):104-11. PubMed ID: 25725179
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Soluble human complement receptor 1 limits ischemic damage in cardiac surgery patients at high risk requiring cardiopulmonary bypass.
    Lazar HL; Bokesch PM; van Lenta F; Fitzgerald C; Emmett C; Marsh HC; Ryan U;
    Circulation; 2004 Sep; 110(11 Suppl 1):II274-9. PubMed ID: 15364875
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Complement activation, cytokines, and adhesion molecules in children undergoing cardiac surgery with or without cardiopulmonary bypass.
    Tárnok A; Hambsch J; Emmrich F; Sack U; van Son J; Bellinghausen W; Borte M; Schneider P
    Pediatr Cardiol; 1999; 20(2):113-25. PubMed ID: 9986887
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Methylprednisolone prevents inflammatory reaction occurring during cardiopulmonary bypass: effects on TNF-alpha, IL-6, IL-8, IL-10.
    Celik JB; Gormus N; Okesli S; Gormus ZI; Solak H
    Perfusion; 2004 May; 19(3):185-91. PubMed ID: 15298427
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impact of pexelizumab, an anti-C5 complement antibody, on total mortality and adverse cardiovascular outcomes in cardiac surgical patients undergoing cardiopulmonary bypass.
    Shernan SK; Fitch JC; Nussmeier NA; Chen JC; Rollins SA; Mojcik CF; Malloy KJ; Todaro TG; Filloon T; Boyce SW; Gangahar DM; Goldberg M; Saidman LJ; Mangano DT;
    Ann Thorac Surg; 2004 Mar; 77(3):942-9; discussion 949-50. PubMed ID: 14992903
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Minimal cardiopulmonary bypass attenuates neutrophil activation and cytokine release in coronary artery bypass grafting.
    Ohata T; Mitsuno M; Yamamura M; Tanaka H; Kobayashi Y; Ryomoto M; Yoshioka Y; Miyamoto Y
    J Artif Organs; 2007; 10(2):92-5. PubMed ID: 17574511
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Calprotectin and complement activation during major operations with or without cardiopulmonary bypass.
    Garred P; Fosse E; Fagerhol MK; Videm V; Mollnes TE
    Ann Thorac Surg; 1993 Mar; 55(3):694-9. PubMed ID: 8452432
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluation of the effect of one large dose of erythropoietin against cardiac and cerebral ischemic injury occurring during cardiac surgery with cardiopulmonary bypass: a randomized double-blind placebo-controlled pilot study.
    Joyeux-Faure M; Durand M; Bedague D; Protar D; Incagnoli P; Paris A; Ribuot C; Levy P; Chavanon O
    Fundam Clin Pharmacol; 2012 Dec; 26(6):761-70. PubMed ID: 21929528
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pretreatment with methylprednisolone improves myocardial protection during on-pump coronary artery bypass surgery.
    Demir T; Ergenoglu MU; Demir HB; Tanrikulu N; Sahin M; Gok E; Korkut K; Demirsoy E
    Heart Surg Forum; 2015 Aug; 18(4):E171-7. PubMed ID: 26334856
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Complement and leukocytes during cardiopulmonary bypass: effects on plasma C3d and C5a, leukocyte count, release of granulocyte elastase and granulocyte chemotaxis.
    Knudsen F; Pedersen JO; Juhl O; Nielsen AH; Jersild C
    J Cardiothorac Anesth; 1988 Apr; 2(2):164-70. PubMed ID: 17171907
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Protection of single-chain urokinase-type plasminogen activator (scu-PA) in aprotinin treated cardiac surgical patients undergoing cardiopulmonary bypass.
    Spannagl M; Dooijewaard G; Dietrich W; Kluft C
    Thromb Haemost; 1995 May; 73(5):825-8. PubMed ID: 7482410
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of pexelizumab in coronary artery bypass graft surgery with extended aortic cross-clamp time.
    Smith PK; Carrier M; Chen JC; Haverich A; Levy JH; Menasché P; Shernan SK; Van de Werf F; Adams PX; Todaro TG; Verrier E
    Ann Thorac Surg; 2006 Sep; 82(3):781-8; discussion 788-9. PubMed ID: 16928483
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Sialic acid is an indicator of inflammation due to cardiopulmonary bypass but not myocardial damage.
    Berkan O; Göl MK; Günay L; Sagaban M
    J Cardiovasc Surg (Torino); 2002 Aug; 43(4):489-93. PubMed ID: 12124560
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.